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De Braekeleer et al. 1 published the first case of acute lymphoblastic leukemia (ALL) associated with a t(1;9)(q24;q34) and showed colocalization of bacterial artificial chromosome (BAC) clones containing the RCSD1 and ABL1 genes, suggesting the presence of a yet undescribed fusion gene. Mustjoki et al. 2 identified a second patient. Sequencing of the PCR products showed that the first three exons of RCSD1 were fused to ABL1, starting at exon 4.
We obtained biological samples from patients diagnosed in Finland, United Kingdom, Kuwait and Ecuador. Five patients (three males and two females) were then included in this study (Table 1) . Their age ranged from 11 to 40 years. All had B-cell ALL. Immunophenotyping showed the blasts to be CD10 þ , CD19 þ , CD22 þ , CD24 þ and CD79a þ . One patient, Pt 4, was lost to follow-up soon after diagnosis. A complete remission was achieved in three patients (Pts 1, 2 and 3) while one patient, Pt 5, was not compliant to treatment and did not achieve complete remission. Three of the four patients for whom data were available (Pts 1, 3 and 5) were still alive, survival ranging from 12 to 97 months. One patient, Pt 1, received bone marrow transplantation 31 months following diagnosis (after a first relapse) and was alive 66 months later. Another patient, Pt 3, had allogeneic hematopoietic stem cell transplantation 4 months following diagnosis but relapsed 12 months later. A third patient, Pt 2, had three bone marrow transplantations, each time following relapse, but died 84 months following diagnosis.
Conventional cytogenetics on bone marrow cells using R-and/ or G-and/or Q-banding revealed a clone containing a t(1;9)(q24;q34) along with a normal clone in four patients while additional material of unknown origin was identified at chromosome Xp22 in the t(1;9)-containing clone in the fifth patient (P1)
Accepted article preview online 20 November 2012; advance online publication, 7 December 2012 (Supplementary Table 1 ). Fluorescent in situ hybridization with BAC clones RP11-232M22 (containing the RCSD1 gene) and RP11-83J21 (containing ABL1) was attempted in four patients (P1, P2, P4 and P5) and showed two fusion signals, suggesting the presence of a RCSD1-ABL1 chimeric gene.
Primers designed by Mustjoki et al. 2 covering the kinase domain of ABL1 and most of the exons of RCSD1 were used on complementary DNA (cDNA) obtained from patients P1, P2, P4 and P5 and extracted from the cytogenetic cell pellet. PCR analysis from leukemic cells showed a sole RCSD1-ABL1-positive product, whereas two RCSD1-ABL1-positive products of slightly different molecular weights were found by Mustjoki et Table 1 ). Sequencing of PCR products showed that the first three exons of RCSD1 were fused to exons 4-11 of ABL1 in all five patients (Supplementary Figure 1) . The shorter PCR product identified in P3 consisted of the first two exons of RCSD1 fused to exon 4 of ABL1, presumably resulting from alternative splicing of the fusion gene. All fusion genes were inframe and encoded the tyrosine kinase domain of ABL1.
Two other cases of B-cell ALL associated with a RCSD1-ABL1 fusion gene were reported in the literature. Inokuchi et al. 3 described a 31-year-old man with t(1;9)(q24;q34) in whom imatinib and dasatinib, combined with dexamethasone, achieved transient clinical effects. Leukemic cells rapidly became refractory to the treatment following the subsequent development of more cytogenetic abnormalities and the patient deceased 6 months following diagnosis. 3 Roberts et al. 4 reported a 15-year-old male in whom RNA-seq analysis showed a RCSD1-ABL1 fusion. No cytogenetic and clinical data were available. 4 In both cases, a chimeric transcript consisting of the first three exons of RCSD1 fused to the ABL1 gene starting from exon 4 was observed, as in the cases described here.
Seven genes are known to fuse to the ABL1 gene. 5 All the fusion genes result from the joining of 5 0 sequences of the partner gene with the 3 0 sequences of the ABL1 gene. The breakpoint occurs in intron 1 or 2 of ABL1 in five different types of fusion gene. Breakpoint in intron 3 of the ABL1 gene was found in the sole case of ALL associated with a SFPQ-ABL1 fusion and in all cases with RCSD1-ABL1 thus far studied. As a consequence, the fusion protein contains part of the SH2 domain of ABL1, the SH1 domain (that has tyrosine kinase function), the three nuclear localization signal domains, the three DNA-binding regions and the F-actin-binding domain. 5 Roumiantsev et al. 6 demonstrated that SH2 domain of BCR-ABL1 was required for efficient induction of CML-like disease in mice. However, it was not required for transformation of primary bone marrow B-lymphoid progenitors in vitro or for induction of B-lymphoid leukemia in mice. 6 This could explain why all the patients thus far reported to carry the RCSD1-ABL1 gene were diagnosed with B-cell ALL.
Furthermore, the retained N-terminal part of the partner proteins contain a coiled-coil domain or a helix-loop-helix domain that is necessary for oligomerization of the fusion ABL1 protein and required for its tyrosine kinase activation. 5 However, although its structure is not well known, the RCSD1 protein does not have a coiled-coil domain or a helix-loop-helix domain. 7 Therefore, it is likely that the RCSD1-ABL1 protein exerts its transforming effects through different mechanisms. Treatment with tyrosine kinase inhibitors, such as imatinib and dasatinib, was only applied in two patients, with variable results. 2, 3 It is therefore difficult to assess the effectiveness of tyrosine kinase inhibitors in patients with RCSD1-ABL1 fusion.
Total RNA was extracted from frozen leukemic cells obtained for patients P1 and P3, reverse transcribed to obtain cDNA that was used as a template to synthesize biotinylated cRNA. Unfortunately, no high-quality RNA suitable for gene expression profiling was available from the other three patients. Labeled cRNA was then fragmented and hybridized to Human HT-12 v3 Expression BeadChips (Illumina, San Diego, CA, USA) according to the manufacturer's instructions. The ArrayMiner 5.3 software (Optimal Design, Brussels, Belgium) was used to compare the gene expression profiles, first, between ALL patients with an ABL1 chimeric gene (RCSD1-ABL1 or BCR-ABL1) and nine patients with a MLL rearrangement; second, between two patients with a RCSD1-ABL1 gene (studied in duplicate) and four Philadelphia-positive B-ALL patients carrying the BCR-ABL1 gene.
Analysis of patients with an ABL1 fusion gene using unsupervised two-dimensional hierarchic clustering algorithm revealed that this group had a distinct signature from the MLL-rearranged group (Supplementary Figure 2) . Among the genes that showed the highest overexpression among the ABL1 group, several of them, such as JAK1, CD27, PTP4A3, TP53INP1, FOXO1 and NLRC5, are involved in cell proliferation, differentiation and apoptosis control (Supplementary Figure 3) .
Gene expression signature of both patients with RCSD1-ABL1 fusion gene was distinct from that of ALL patients with BCR-ABL1 gene (Supplementary Figure 2) . Several genes overexpressed in the RCSD1-ABL1 group compared with the BCR-ABL1 group code transcription factors such as AFF1 and PBX4 (Supplementary Figure 4) . AFF1 (alias AF4-AF4/FMR2 family, member 1) is part of a higher order complex, known as the AEP complex, also containing other AFF1 and ENL family proteins and PTEF-b (positive transcription elongation factor b). 8 This complex promotes CD133 transcription, a gene encoding a pentaspan transmembrane glycoprotein thought to function in maintaining stem cell properties by suppressing differentiation. Overexpression of AFF1 would lead to higher CD133 transcript levels, inducing ALL cell growth and survival. 
